Michigan House Bill HB4333

Michigan 2025-2026 Regular Session

• Introduced: 4/17/25
• Refer: 4/17/25

Caption

Criminal procedure: sentencing guidelines; sentencing guidelines for conducting pathogen enhancement engineering or research; provide for. Amends sec. 13k, ch. XVII of 1927 PA 175 (MCL 777.13k). TIE BAR WITH: HB 4332'25

Impact

The amendments introduced by HB 4333 are significant for state laws pertaining to biomedical research and the ethical treatment of human subjects. By solidifying the categories of felonies and corresponding penalties, the bill seeks to deter potential misconduct in the research field, especially concerning new and emerging technologies. It emphasizes the necessity of informed consent and ethical practices in research environments. This marks a critical step in aligning criminal penalties with contemporary ethical standards in the scientific community.

Summary

House Bill 4333 proposes amendments to the Michigan Code of Criminal Procedure, specifically focusing on sentencing guidelines for various felonies related to pathogen enhancement engineering and biomedical research. This bill aims to provide a clearer legal framework governing activities involving human embryos, fetuses, and neonates in the context of research conducted with pathogens. Notably, it includes specific statutes that address severe penalties for those involved in unethical research practices, such as conducting nontherapeutic research using living human embryos or engaging in fraudulent activities leading to patient death.

Contention

While the bill generally aims to enhance regulatory frameworks, it has stirred discussion regarding its implications for research institutions and the boundaries it may impose on scientific inquiry. Proponents argue that stricter guidelines are essential for protecting vulnerable populations and ensuring ethical compliance. However, opponents express concerns about the potential chilling effect on legitimate research that could arise from stringent penalties, which they fear might discourage important medical advancements. Balancing regulation with innovation remains a pivotal point of contention among legislators, researchers, and ethical committees.